NEW YORK (GenomeWeb) – Synthetic promoter firm Synpromics announced today that it has completed a £5.2 million ($6.6 million) financing round.

Participants in the round included existing investors Calculus Capital, the Scottish Investment Bank, and private shareholders, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.